Genetic engineering strain for producing deoxyviolacein as well as construction method and application of genetic engineering strain

By knocking out genes involved in the tryptophan synthesis pathway in Escherichia coli and expressing genes related to the synthesis of deoxyviolacein, a genetically engineered strain was constructed, solving the problem of low deoxyviolacein yield and achieving efficient and stable industrial production.

CN118979050APending Publication Date: 2024-11-19JIANGSU HUACHENG BIOTECHNOLOGY CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411047707.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-01
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

In existing technologies, deoxypurpuric acid has low yields and is difficult to isolate in wild strains. Natural producers have complex nutritional requirements and pathogenicity, making it difficult to meet the needs of industrial production.

Method used

Using Escherichia coli as the starting strain, genes related to the competitive pathway of tryptophan synthesis and metabolism were knocked out, and genes vioA, vioB, vioC, and vioE related to deoxyviocin synthesis were expressed. Genetically engineered strains were constructed using CRISPR/Cpf1 gene editing technology, and enzyme expression and culture conditions were optimized to increase the yield of deoxyviocin.

Benefits of technology

The method achieves efficient and stable production of deoxyviolacein, with a yield of 3.28 g/L, demonstrating potential for industrial production and solving the problems of low yield and insufficient purity in existing technologies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118979050A_ABST
    Figure CN118979050A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of bioengineering, and particularly discloses a gene engineering strain for producing deoxyviolacein as well as a construction method and application of the gene engineering strain. The gene engineering strain for producing deoxyviolacein provided by the invention takes escherichia coli as a starting strain, at least one gene in tnaA gene, trpR gene or pheA gene in a host cell is knocked out, and meanwhile, a vioA gene, a vioB gene, a vioC gene and a vioE gene are heterologously expressed; wherein the four genes of the vioA, the vioB, the vioC and the vioE are derived from chromobacterium violaceum. By reasonably designing and knocking out host cell competitive pathway genes, preferably selecting heterologous expression gene types, optimizing construction and introduction methods of recombinant plasmids and optimizing enzyme expression quantity and tryptophan dosage, a synthetic pathway for producing deoxyviolacein, which is good in stability, short in culture period, high in synthetic efficiency and low in cost, is provided. The method is suitable for biosynthesis of deoxyviolacein.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of bioengineering, and relates to a genetically engineered strain producing deoxyviolacein, in particular to a genetically engineered strain producing deoxyviolacein, and a construction method and application thereof. Background Art

[0002] Deoxyviolacetin is a purple secondary metabolite produced by a variety of bacteria. It has attracted great attention due to its good inhibitory effect on the biological activity of tumor cells, Gram-positive bacteria and plant pathogenic fungi. In addition, due to its good coloring effect, deoxyviolacetin can also be used as a biological dye and has broad application prospects in the fields of food, medical treatment, printing and dyeing industry and cosmetics.

[0003] Since deoxypurpurogenin always appears as a minor component, its content in wild production strains is 3-10 times lower than that of purpurogenin, and it is difficult to separate enough deoxypurpurogenin to study its properties and functions, so there is still little research on its characteristics and functions. In order to meet the growing demand for deoxypurpurogenin, it is necessary to develop a high-titer and pure deoxypurpurogenin production process. However, the deoxypurpurogenin yield of natural producers such as purpurogenin is very low, and these natural producers also show complex nutritional requirements and undesirable pathogenic traits to varying degrees, and are difficult to be directly used for production and purification.

[0004] Pemberton et al. pioneered the successful heterologous expression of the vioABCDE pathway in Escherichia coli, which was an early milestone in the production of violacein or deoxyviolacein. Escherichia coli has a clear genetic background, can efficiently express foreign genes, has simple related technical operations, and has a short culture cycle. It is one of the most commonly used model chassis microorganisms for engineered production of chemicals. L-tryptophan is the main precursor for the synthesis of deoxyviolacein, so it is crucial to maintain a suitable high concentration of L-tryptophan flux. Using tryptophan as a substrate, finding a deoxyviolacein synthesis pathway suitable for Escherichia coli and optimizing the expression levels of key pathway enzymes is easy to scale up and is a promising and efficient production strategy. Summary of the invention

[0005] Aiming at the problem that the amount of deoxyviolacetin synthesized by existing wild strains is small and the currently reported synthesis pathways cannot meet the demand for industrial production of deoxyviolacetin, the present invention provides a genetically engineered strain for producing deoxyviolacetin, which provides an effective way for commercial production of deoxyviolacetin using sufficient Escherichia coli;

[0006] Another object of the present invention is to provide a method for constructing the above-mentioned genetically engineered strain producing deoxypurpurogenin, so as to achieve the goal of accurately and effectively constructing the strain;

[0007] Another object of the present invention is to provide the use of the above genetically engineered strain in the production of deoxyviolacein, and to provide a production route for synthesizing deoxyviolacein.

[0008] In order to achieve the above-mentioned object of the invention, the embodiment of the present invention adopts the following technical solution:

[0009] A genetically engineered strain for producing deoxyviolacein, which uses Escherichia coli as a starting strain, knocks out at least one gene related to the competition pathway for tryptophan synthesis and metabolism in the Escherichia coli, and simultaneously expresses the coding genes for enzymes related to the biosynthesis of deoxyviolacein and its derivatives;

[0010] Wherein, the genes related to the tryptophan competition pathway include tnaA gene, trpR gene or pheA gene;

[0011] The coding genes for enzymes related to the biosynthesis of deoxyviolacetin and its derivatives include vioA gene, vioB gene, vioC gene and vioE gene;

[0012] The vioA gene, vioB gene, vioC gene and vioE gene are derived from Chromobacterium violaceum and are all codon optimized;

[0013] Wherein, the Genebank ID of the tnaA gene is 948221;

[0014] The Genebank ID of the trpR gene is 948917;

[0015] The Genebank ID of the pheA gene is 947081;

[0016] The nucleotide sequence of the vioA gene is shown in SEQ ID NO.1;

[0017] The nucleotide sequence of the vioB gene is shown in SEQ ID NO.2;

[0018] The nucleotide sequence of the vioC gene is shown in SEQ ID NO.3;

[0019] The nucleotide sequence of the vioE gene is shown in SEQ ID NO.4.

[0020] Preferably, the Chromobacterium violaceum is Chromobacterium violaceum ATCC 12472; and / or

[0021] The Escherichia coli is Escherichia coli BL21 (DE3).

[0022] Preferably, the heterologous expression comprises using a strong promoter to control the expression of the coding gene of the enzyme related to the biosynthesis of the deoxyviolacein derivative.

[0023] Further preferably, the strong promoter includes promoter P tac ; The promoter P tac The nucleotide sequence is shown as SEQ ID NO.5.

[0024] Preferably, the RBS1 sequence is used to express the genes vioA and vioB in tandem; the RBS2 sequence is used to express the genes vioE and vioC in tandem;

[0025] The nucleotide sequence of the RBS1 is shown in SEQ ID NO.6; the nucleotide sequence of the RBS2 is shown in SEQ ID NO.7.

[0026] The present invention also provides a method for constructing the above-mentioned genetically engineered strain producing deoxypurpurogenin, and the construction method comprises the following steps:

[0027] Step 1. Preparation of knockout E. coli strains

[0028] Using CRISPR / Cpf1 gene editing technology, knocking out at least one of the tnaA gene, the trpR gene or the pheA gene in the Escherichia coli to obtain a knockout Escherichia coli strain;

[0029] Step 2: Construction of recombinant expression vector

[0030] Using the genome of Chromobacterium violaceum as a template, a plasmid containing vioA gene, vioB gene, vioC gene and vioE gene was constructed to obtain a recombinant expression vector;

[0031] Step 3: Construction of a genetically engineered strain producing deoxypurpurogenin

[0032] The recombinant expression vector is introduced into the knockout Escherichia coli strain to obtain the genetically engineered strain producing deoxypurpurogenin.

[0033] Preferably, the step 1 specifically includes the following steps:

[0034] S11. Using the E. coli BL21 (DE3) genome as a template, connect the upstream and downstream fragments of the trpR gene to obtain donor DNA fragment 1;

[0035] S12. The N23 sequence on the plasmid pcrEG was replaced with the N23' sequence complementary to the specific 23 bp sequence on trpR, and trpR-N23-F / R was used as primers to obtain the plasmid pcrEG-TrpR with targeting trpR;

[0036] S13. The pEcCpf1 plasmid was transformed into competent E. coli cells to obtain BL21-pEcCpf1 strain;

[0037] S14. Introduce the pcrEG-TrpR plasmid and donor DNA fragment 1 into the electroporation competent cells of the BL21-pEcCpf1 strain, verify by colony PCR, pick the strain with successful knockout and culture it, remove the pcrEG-TrpR and pEcCpf1 plasmids, and obtain the Escherichia coli with knockout of the trpR gene, which is the B1 strain.

[0038] Preferably, the step 1 further comprises taking the B1 strain as the starting strain, knocking out at least one of the pheA gene and / or the tnaA gene, and constructing a knockout Escherichia coli strain;

[0039] The step 2 comprises using the genome of Chromobacterium violaceum as a template, synthesizing genes vioA, vioB, vioE and vioC by codon optimization; wherein, the vioA gene and the vioB gene can be expressed in series by using the RBS1 sequence, and the vioE gene and the vioC gene can be expressed in series by using the RBS2 sequence; and further constructing the plasmid pCO-tac-vioA-vioB-tac-vioE-vioC;

[0040] Using pETDuet-1 plasmid as a vector, at least one of the plasmids pET-tac-vioA, pET-tac-vioB, pET-tac-vioE, pET-tac-vioC, pET-tac-vioA-vioB or pET-tac-vioE-vioC was obtained by assembling two fragments.

[0041] Preferably, the step three includes introducing the plasmid pCO-tac-vioA-vioB-tac-vioE-vioC and at least one of pET-tac-vioA, pET-tac-vioB, pET-tac-vioE, pET-tac-vioC, pET-tac-vioA-vioB or pET-tac-vioE-vioC into the knockout Escherichia coli strain.

[0042] The present invention also provides the use of the above-mentioned genetically engineered strain producing deoxyviolacetin or the genetically engineered strain producing deoxyviolacetin obtained by the construction method of the above-mentioned genetically engineered strain producing deoxyviolacetin in synthesizing deoxyviolacetin.

[0043] Preferably, in the above application, the genetically engineered strain producing deoxyviolacein is fermented and cultured in a fermentation medium containing tryptophan to produce deoxyviolacein; wherein the concentration of tryptophan in the fermentation medium containing tryptophan is 5 to 24 mM; and the carbon source in the fermentation medium is glycerol or glucose.

[0044] The engineered strain was fermented at 37°C until OD 600 After the pH value is 0.6-0.8, IPTG is added as an inducer; the final concentration of the added IPTG in the fermentation broth is 0.05-1.0 mM; the fermentation culture condition after the induction is 18-22° C. for at least 48 hours.

[0045] Due to the adoption of the above technical solution, the present invention has the following technical advances compared with the prior art:

[0046] (1) The present invention introduces the coding genes of enzymes related to the biosynthesis of deoxyviolacein and its derivatives in Chromobacterium violaceum into Escherichia coli in which the coding genes of related enzymes in the tryptophan competition pathway have been knocked out, so that the recombinant Escherichia coli efficiently expresses the genes related to the production of deoxyviolacein, providing a deoxyviolacein synthesis pathway with good stability, short culture cycle, high synthesis efficiency and low cost;

[0047] (2) When constructing a genetically engineered strain producing deoxyviolacein, the present invention firstly knocks out genes of enzymes related to tryptophan synthesis and metabolic competition bypass in the host cell, including the tryptophan enzyme gene tnaA, the tryptophan repressor protein encoding gene trpR, and the mycolate mutase (CM) / prephenate dehydratase (PD) bifunctional enzyme protein gene pheA, the purpose of which is to reduce the decomposition of tryptophan in the host cell, so as to facilitate the subsequent tryptophan metabolic pathway in the host cell to proceed in a direction that is conducive to the synthesis of the target product deoxyviolacein; secondly, in terms of gene selection, the vioA, vioB, vioC and vioE genes related to the four enzymes involved in the entire synthesis pathway of deoxyviolacein and its derivatives are introduced into the heterologous nucleotide sequence of Escherichia coli, and these four genes provide genetic guarantees for the heterologous synthesis of deoxyviolacein; thirdly, when the four encoding genes of the four enzymes are introduced into the host cell, The constructed vioE-RBS-vioC gene cluster (including vioC and vioE genes) is inserted between the NdeI and MfeI sites of the second position of the multiple cloning site of the pCO-tac-vioAB-tac (including vioA and vioB) plasmid vector to obtain the recombinant plasmid pCO-tac-vioA-vioB-tac-vioE-vioC, which is then introduced into the knockout Escherichia coli to improve the stability of the foreign gene during the insertion process, thereby improving the stability of the engineered strain; fourth, by increasing the plasmid and optimizing the enzyme expression amount to increase the yield of deoxyviolacein, such as the introduction of the plasmid pET-tac-vioA-vioB, the yield of deoxyviolacein can be significantly increased; finally, in terms of promoter selection, the preferred Ptac of the present invention can effectively control the expression of the genes vioA, vioB, vioC and vioE;

[0048] (3) The present invention optimizes the culture medium and fermentation conditions so that the obtained engineered strain can produce 3.28 g / L of Deoxypurpurogenous Bacillus in M9-YE culture medium containing tryptophan and under specific fermentation conditions, and has the potential for industrial production of Deoxypurpurogenous Bacillus. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0050] Figure 1 is a standard curve diagram of deoxyviolacein in the present invention;

[0051] Figure 2is a skeleton diagram of the plasmid pCO-tac-vioA-vioB-tac-vioE-vioC in Example 2 of the present invention;

[0052] Figure 3 The bar graph is a graph showing the yield of deoxyviolacein by strains BEC, B1EC, B2EC and B3EC in the fermentation system in Example 3 of the present invention;

[0053] Figure 4 The bar graph is a graph of the deoxyviolacein production of the strain B3EC in four culture media in Example 3 of the present invention;

[0054] Figure 5 The bar graph is a graph of the production of deoxyviolacein by the strain B3EC in Example 3 of the present invention in the M9-YE medium supplemented with tryptophan at different concentrations;

[0055] Figure 6 The figure is a bar graph of the yield of deoxypurpurogenin by different engineered strains in M9-YE medium in Example 3 of the present invention;

[0056] Figure 7 This is a color comparison chart of a deoxyviolacein sample extracted from the fermentation broth obtained after the strain B3EC-AB was fermented in M9-YE medium and diluted 150 times, a deoxyviolacein standard sample and a blank control;

[0057] Figure 8 This is a picture of the powder obtained after freeze-drying and grinding of the fermentation broth of strain B3EC-AB after centrifugation. DETAILED DESCRIPTION

[0058] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0059] The plasmid, endonuclease, PCR enzyme, column DNA extraction kit and DNA gel recovery kit used in the present invention are commercial products, and the specific operations are carried out according to the kit instructions. Colony PCR, nucleic acid agarose gel electrophoresis, protein SDS-PAGE gel electrophoresis, heat shock transformation, electrotransformation and preparation of competent cells and extraction and storage of bacterial genomes and other conventional operation methods are carried out according to Molecular Cloning: A Laboratory Manual (Fourth Edition).

[0060] The culture medium, fermentation conditions, deoxypurpurogenin detection method, plasmid and strain selected in the present invention are as follows:

[0061] (I) Culture medium

[0062] (1) LB liquid medium: 5 g / L yeast extract, 10 g / L peptone, and 10 g / L sodium chloride.

[0063] (2) LB solid medium: 10 g / L peptone, 5 g / L yeast extract, 10 g / L sodium chloride, and 15 g / L agar powder.

[0064] (3) M9-YE medium: 17.1 g / L disodium hydrogen phosphate, 3 g / L potassium dihydrogen phosphate, 0.5 g / L sodium chloride, 1 g / L ammonium chloride, 1 g / L yeast extract, 1 mM magnesium sulfate, 0.1 mM calcium chloride and 10 g / L glucose.

[0065] (4) R / 2 medium: 3 g / L yeast extract, 20 g / L glycerol, 3 g / L ammonium sulfate, 2 g / L diammonium hydrogen phosphate, 6.75 g / L potassium dihydrogen phosphate, 0.85 g / L citric acid, 0.7 g / L magnesium sulfate heptahydrate, 5 mL / L trace metal solution (TMS), pH adjusted to 6.8 with sodium hydroxide.

[0066] Trace metal solution (TMS) includes: 10 g / L ferrous sulfate, 2.25 g / L zinc sulfate heptahydrate, 1.0 g / L anhydrous copper sulfate, 0.35 g / L manganese sulfate monohydrate, 0.23 g / L sodium borate decahydrate, 0.11 g / L ammonium molybdate, 2.0 g / L calcium chloride dihydrate, dissolved in 5 M hydrochloric acid.

[0067] (5) MR medium: 6.67 g / L potassium dihydrogen phosphate, 4 g / L diammonium hydrogen phosphate, 0.8 g / L magnesium sulfate heptahydrate, 0.8 g / L citric acid and 10 ml / L trace metal elements. Trace metal elements include: 10 g / L ferrous sulfate heptahydrate, 1.35 g / L anhydrous calcium chloride, 2.2 g / L zinc sulfate heptahydrate, 0.58 g / L manganese sulfate tetrahydrate, 1 g / L copper sulfate pentahydrate, 0.2 g / L sodium borate decahydrate, 0.1 g / L ammonium molybdate tetrahydrate, and 10 g / L glucose.

[0068] (6) Antibiotic concentration: kanamycin 50 mg / L, ampicillin 100 mg / L.

[0069] (II) Fermentation production of deoxypurpurogenin

[0070] The constructed strain was inoculated into 4 mL LB liquid medium containing kanamycin or ampicillin and kanamycin, and cultured overnight at 37°C, 210 rpm for 12 h to obtain seed solution. 500 μL of seed solution was inoculated into 25 mL fermentation medium, and cultured at 37°C, 210 rpm until OD 600 The pH value was 0.6-0.8, and IPTG was added at a final concentration of 0.2 mM. The induction culture was continued at 20°C and 210 rpm for 48 h.

[0071] (III) Deoxypurpurogenin detection

[0072] The entire fermentation system was mixed and sampled (1 mL was sampled from each fermentation system), centrifuged at 12000 rpm for 10 min and the precipitate was collected. The precipitate was washed twice with 100% methanol and centrifuged at 12000 rpm for 5 min. After the methanol was fully evaporated, 2 mL of DMSO was added and the precipitate was dissolved by ultrasonic disruption (when the extraction was completed, the precipitate had no color), centrifuged at 12000 rpm for 5 min and the supernatant was collected, and the absorbance at 568 nm was detected by a spectrophotometer.

[0073] Use deoxypurpurogenin standard to make a standard curve. The standard curve of deoxypurpurogenin is as shown in the figure below. Figure 1 As shown, the standard curve equation is y = 0.0339x-0.0018, R 2 =0.9999, x represents the absorbance at 568 nm, and y represents the concentration of deoxyviolacein (g / L).

[0074] The yield of deoxyviolacein in the fermentation system was calculated based on the absorbance value at 568 nm and the standard curve equation.

[0075] (IV) Plasmids and strains

[0076] The CRISPR / Cpf1 dual-plasmid gene editing system has been published in the literature: Zhu X, Wu Y, Lv X. Combining CRISPR–Cpf1 and Recombineering Facilitates Fast and Efficient Genome Editing in Escherichia coli[J]. ACS Synthetic Biology, 2022(5):11.

[0077] The statistical table of the strains involved in the present invention is shown in Table 1 below.

[0078] Table 1 The strains involved in the present invention

[0079] Strain name Host contains plasmids and genotypes B1 E.coliBL21(DE3)ΔtrpR B2 E.coli BL21(DE3)ΔpheAΔtrpR B3 E.coliBL21(DE3)ΔpheAΔtrpRΔtnaA BEC E.coliBL21(DE3) containing plasmid pCO-tac-vioA-vioB-tac-vioE-vioC B1EC B1 contains plasmid pCO-tac-vioA-vioB-tac-vioE-vioC B2EC B2 contains plasmid pCO-tac-vioA-vioB-tac-vioE-vioC B3EC B3 contains plasmid pCO-tac-vioA-vioB-tac-vioE-vioC B3EC-A B3 contains plasmids pCO-tac-vioA-vioB-tac-vioE-vioC and pET-tac-vioA B3EC-B B3 contains plasmids pCO-tac-vioA-vioB-tac-vioE-vioC and pET-tac-vioB B3EC-E B3 contains plasmids pCO-tac-vioA-vioB-tac-vioE-vioC and pET-tac-vioE B3EC-C B3 contains plasmids pCO-tac-vioA-vioB-tac-vioE-vioC and pET-tac-vioC B3EC-AB B3 contains plasmids pCO-tac-vioA-vioB-tac-vioE-vioC and pET-tac-vioA-vioB B3EC-EC B3 contains plasmids pCO-tac-vioA-vioB-tac-vioE-vioC and pET-tac-vioE-vioC

[0080] In order to better illustrate the present invention, further examples are given below.

[0081] Example 1

[0082] The present invention provides a method for constructing a genetically engineered strain that produces deoxypurpurogenin. First, a knockout Escherichia coli strain is prepared. This embodiment provides a method for preparing a knockout Escherichia coli strain, which is specifically as follows:

[0083] Using CRISPR / Cpf1 gene editing technology, at least one of the tnaA gene encoding the tryptophan enzyme TnaA, the trpR gene encoding the tryptophan repressor protein TrpR, or the pheA gene encoding the bifunctional enzyme protein gene of mycolate mutase (CM) / prephenate dehydratase (PD) in Escherichia coli BL21 (DE3) is knocked out to obtain a knockout Escherichia coli strain. Specifically, the gene trpR encoding the tryptophan repressor protein TrpR, the gene tnaA encoding the tryptophan enzyme TnaA, and the gene pheA encoding the bifunctional enzyme protein of mycolate mutase (CM) / prephenate dehydratase (PD) in Escherichia coli BL21 (DE3) are knocked out to varying degrees by the CRISPR / Cpf1 gene editing system, and recombinant bacteria B1, B2 and B3 are obtained respectively (the primer sequences involved are shown in Table 2). This embodiment takes the B2 strain with knockout genes trpR and pheA as an example, and the specific steps are as follows:

[0084] (1) Using the Escherichia coli BL21 genome as a template, using ΔtrpR-up-F / R and ΔtrpR-down-F / R primers, the upstream and downstream fragments of the trpR gene were amplified by PCR technology, and the fragments were recovered and purified by gel recovery; the fragments obtained by connecting the upstream and downstream amplifications by overlapping PCR were used as donor DNA fragments, recorded as donor DNA fragment 1;

[0085] (2) Using PCR amplification technology, trpR-N23-F / R was used as primers to replace the N23 sequence on the plasmid pcrEG with a specific 23bp sequence on the trpR gene (from the 68th base pair to the 90th base pair at the 5' end of the gene, TCGACCTGCTTAAGAATGCCTAC). The PCR product was removed from the original plasmid template DNA using DpnⅠ enzyme, and was transformed into the competent Escherichia coli JM109 using the heat shock transformation method. It was then spread on LB solid medium containing spectinomycin and cultured at 37°C for 8 to 12 hours (this example is described using a culture time of 12 hours as an example), and then a single colony was picked for expansion culture, and the plasmid was extracted and sequenced to obtain the plasmid pcrEG-TrpR with targeting trpR;

[0086] (3) The pEcCpf1 plasmid was transferred into the competent E. coli BL21 (DE3), and the transformed bacterial solution was spread on the LB solid medium containing kanamycin, and cultured in a 37°C incubator for 8 to 12 hours (the culture time is 12 hours as an example), to obtain the BL21-pEcCpf1 strain;

[0087] (4) preparing the BL21-pEcCpf1 strain into electroporation competent cells;

[0088] (5) The pcrEG-TrpR plasmid and donor DNA fragment 1 were electroporated into electroporation competent cells of Escherichia coli BL21-pEcCpf1, spread on LB solid medium containing kanamycin and spectinomycin, cultured at 37°C for 24 h, and PCR colony verification was performed to obtain positive clone colonies;

[0089] (6) The positive clones were picked into 4 mL LB liquid medium containing a final concentration of 10 mM rhamnose and 4 μL Kan, and cultured at 37°C for 12 h to remove the pcrEG-TrpR plasmid, thereby obtaining Escherichia coli BL21 (DE3) ΔtrpR containing the pEcCpf1 plasmid and the knockout trpR gene, which was used for the next round of knockout;

[0090] (7) The bacteria that have been successfully verified to have removed the pcrEG-TrpR plasmid were inoculated into a liquid LB medium containing 5 g / L glucose and cultured at 37°C, 200 rpm for 12 h. Then, about 5 μL of the bacterial liquid was streaked on a plate containing 5 g / L glucose and 10 g / L sucrose and cultured at 37°C for 12 h. After removing the pEcCpf1 plasmid, the trpR gene-knockout Escherichia coli BL21 (DE3) ΔtrpR was obtained, which was recorded as strain B1;

[0091] (8) Using the Escherichia coli BL21 genome as a template and ΔpheA-up-F / R and ΔpheA-down-F / R as primers, the upstream and downstream fragments of pheA were amplified by PCR, respectively. The fragments were purified by gel recovery, and the fragments obtained by upstream and downstream amplification were connected by overlapping PCR as donor DNA fragments, which were recorded as donor DNA fragment 2;

[0092] (9) The N23 sequence on the plasmid pcrEG was replaced with a specific 23 bp sequence on the pheA gene (from the 790th base pair to the 812th base pair at the 5' end of the gene, CAGGTACTGGAGCGTATTGAAGC) by PCR amplification technology, and pheA-N23-F / R was used as primers to obtain the plasmid pcrEG-PheA carrying the targeted pheA gene;

[0093] (10) The correctly sequenced plasmid pcrEG-PheA and donor DNA fragment 2 were electroporated into B1 strain electroporation competent cells, spread on LB solid medium containing kanamycin and spectinomycin, cultured at 37°C for 24 h, and PCR colony verification was performed;

[0094] (11) The positive clones obtained in step (10) were transferred to a 4 mL LB liquid test tube (containing a final concentration of 10 mM rhamnose and 4 μL Kan), and cultured at 37° C. for 12 h to remove the pcrEG-PheA plasmid;

[0095] The recombinant E. coli containing plasmid pEcCpf1 was used for the next round of knockout.

[0096] (12) The bacteria that were verified to have successfully removed the pCrEG-PheA plasmid were inoculated into LB liquid culture medium and cultured at 37°C, 200 rpm for 12 h. Then, 5 μL of the above bacterial liquid was streaked on a solid LB plate containing 5 g / L glucose and 10 g / L sucrose and cultured at 37°C for 12 h. After removing the pEcCpf1 plasmid, an engineered strain with successful knockout of the trpR gene and pheA gene was obtained, which was named B2 strain.

[0097] (13) Based on strain B2, the tnaA gene in the strain was knocked out using the same method (primers ΔtnaA-up-F / R, ΔtnaA-down-F / R, tnaA-N23-F / R) to obtain the Escherichia coli knockout strain B3.

[0098] Wherein, the Genebank ID of the tnaA gene is 948221;

[0099] The Genebank ID of the trpR gene is 948917;

[0100] The Genebank ID of the pheA gene is 947081;

[0101] Among them, the primers selected for the preparation of the knockout Escherichia coli strain are shown in Table 2 below.

[0102] Table 2 Statistics of primers used for the preparation of knockout Escherichia coli strains

[0103]

[0104]

[0105] Example 2

[0106] The present invention provides a method for constructing a genetically engineered strain producing deoxyviolacetin. After preparing a knockout Escherichia coli strain, a recombinant expression vector is constructed and a genetically engineered strain producing deoxyviolacetin is constructed. This embodiment provides a method for constructing a recombinant expression vector and a method for constructing a genetically engineered strain producing deoxyviolacetin.

[0107] 1. Construction of recombinant expression vector:

[0108] The genome of Chromobacterium violaceum (ATCC 12472) is used as a template to construct a plasmid containing vioA gene, vioB gene, vioC gene and vioE gene to obtain a recombinant expression vector. The specific steps include:

[0109] (1) The genome of Chromobacterium violaceum ATCC 12472 was used as a template and codons were optimized before entrusting Suzhou Jinweizhi Biotechnology Co., Ltd. to synthesize plasmids pCO-tac-vioAB-tac, pCO-tac-tac-vioE, and pCD-tac-vioCD;

[0110] (2) Using plasmids pCO-tac-tac-vioE and pCD-tac-vioCD as templates, primers pCO-2-vioE-R / pCO-vioE-RBS-R and pCO-RBS-vioC-F / pCO-vioC-2R were used to amplify the vioE-RBS-vioC gene cluster;

[0111] (3) Insert the vioE-RBS-vioC gene cluster between the NdeI and MfeI sites of the second position of the multiple cloning site of the plasmid pCO-tac-vioAB-tac, and sequence and verify to obtain the plasmid pCO-tac-vioA-vioB-tac-vioE-vioC, that is, the recombinant expression vector. The skeleton diagram of the plasmid pCO-tac-vioA-vioB-tac-vioE-vioC is shown in FIG. Figure 2 As shown;

[0112] (4) Similarly, using the pETDuet-1 plasmid as a vector, pET-tac-vioA, pET-tac-vioB, pET-tac-vioE, pET-tac-vioC, pET-tac-vioA-vioB and pET-tac-vioE-vioC were constructed by two-fragment assembly.

[0113] 2. Construction of genetically engineered strains producing deoxypurpurogenin

[0114] The recombinant plasmid pCO-tac-vioA-vioB-tac-vioE-vioC prepared above was transformed into the recombinant Escherichia coli BL21 (DE3) and the recombinant strains B1, B2, and B3 constructed in Example 1 to obtain four different engineered strains BEC, B1EC, B2EC, and B3EC.

[0115] Subsequently, the plasmids pET-tac-vioA, pET-tac-vioB, pET-tac-vioE, pET-tac-vioC, pET-tac-vioA-vioB and pET-tac-vioE-vioC prepared in Example 2 were respectively transformed into the recombinant Escherichia coli strain B3EC to obtain 6 different engineered strains B3EC-A, B3EC-B, B3EC-E, B3EC-C, B3EC-AB and B3EC-EC.

[0116] Wherein, the nucleotide sequence of the vioA gene is shown as SEQ ID NO.1;

[0117] The nucleotide sequence of the vioB gene is shown in SEQ ID NO.2;

[0118] The nucleotide sequence of the vioC gene is shown in SEQ ID NO.3;

[0119] The nucleotide sequence of the vioE gene is shown in SEQ ID NO.4.

[0120] The above plasmid uses a strong promoter (Promoter P tac ) controls the expression of genes vioA, vioB, vioC and vioE, the promoter P tac The nucleotide sequence is shown in SEQ ID NO.5.

[0121] The RBS1 sequence is used to express the genes vioA and vioB in series, and the RBS2 sequence is used to express the genes vioE and vioC in series; wherein the nucleotide sequence of the RBS1 is shown in SEQ ID NO.6; and the nucleotide sequence of the RBS2 is shown in SEQ ID NO.7.

[0122] The statistics of primers used for the construction of recombinant expression vectors are shown in Table 3.

[0123] Table 3 Statistics of primers used in the construction of recombinant expression vectors

[0124]

[0125]

[0126] Example 3

[0127] This embodiment provides the use of a genetically engineered strain producing deoxyviolacein in the synthesis of deoxyviolacein, specifically:

[0128] 1. Production of deoxypurpurogenin by shake flask fermentation

[0129] BEC, B1EC, B2EC and B3EC strains were inoculated into 4 mL LB liquid medium containing the corresponding antibiotics, and cultured overnight at 37°C, 210 rpm for 12 h to obtain seed solution. 500 μL of seed solution was inoculated into 25 mL fermentation medium and cultured at 37°C, 210 rpm until OD 600 The pH value was 0.6-0.8, and IPTG was added at a final concentration of 0.2 mM for induction. The temperature was lowered to 20°C and the induction culture was continued at 210 rpm for 24 h.

[0130] According to the deoxyviolacein detection method described in this specification, the deoxyviolacein content in the fermentation system was detected. The BEC, B1EC, B2EC and B3EC engineered strains constructed in Example 2 were inoculated into LB liquid culture medium, cultured overnight at 37°C, 210rpm for 12h to obtain seed liquid, and 500 μL of seed liquid was inoculated into 25 mL of fermentation medium to explore the effects of different strains on the deoxyviolacein yield, while other culture conditions remained unchanged.

[0131] The whole fermentation system was mixed and sampled (1 mL was sampled from each fermentation system), centrifuged at 12000 rpm for 10 min and the precipitate was collected. The precipitate was fully washed twice with 100% methanol, centrifuged at 12000 rpm for 5 min, and after the methanol was fully volatilized, 2 mL of DMSO was added and the precipitate was dissolved by ultrasonic disruption (when the extraction was completed, the precipitate had no color), centrifuged at 12000 rpm for 5 min and the supernatant was collected. The absorbance at 568 nm was detected by a spectrophotometer, and the yield of deoxyviolacein in the fermentation system was calculated according to the deoxyviolacein standard curve equation. The bar graph of deoxyviolacein yield of strains BEC, B1EC, B2EC and B3EC in the fermentation system is shown in the figure. Figure 3 shown.

[0132] 2. Optimization of culture medium

[0133] Four different types of culture media, M9-YE, R / 2, MR and LB, were used to ferment the B3EC engineered bacteria. The culture media formulas are as follows:

[0134] Fermentation medium M9-YE: 17.1 g / L disodium hydrogen phosphate, 3 g / L potassium dihydrogen phosphate, 0.5 g / L sodium chloride, 1 g / L ammonium chloride, 1 g / L yeast extract, 1 mM magnesium sulfate, 0.1 mM calcium chloride and 10 g / L glucose.

[0135] Fermentation medium R / 2: 3g / L yeast extract, 3g / L ammonium sulfate, 2g / L diammonium hydrogen phosphate, 6.75g / L potassium dihydrogen phosphate, 0.85g / L citric acid, 0.7g / L magnesium sulfate heptahydrate and 5ml / L trace metal elements. Trace metal elements include 5mol / L hydrochloric acid, 10g / L ferrous sulfate heptahydrate, 2.25g / L zinc sulfate heptahydrate, 1g / L copper sulfate pentahydrate, 0.5g / L manganese sulfate pentahydrate, 0.23g / L sodium borate decahydrate, 2.0g / L calcium chloride dihydrate, 0.1g / L ammonium molybdate tetrahydrate, and 20g / L glycerol.

[0136] Fermentation medium MR: 6.67 g / L potassium dihydrogen phosphate, 4 g / L diammonium hydrogen phosphate, 0.8 g / L magnesium sulfate heptahydrate, 0.8 g / L citric acid and 10 ml / L trace metal elements. Trace metal elements include: 10 g / L ferrous sulfate heptahydrate, 1.35 g / L anhydrous calcium chloride, 2.2 g / L zinc sulfate heptahydrate, 0.58 g / L manganese sulfate tetrahydrate, 1 g / L copper sulfate pentahydrate, 0.2 g / L sodium borate decahydrate, 0.1 g / L ammonium molybdate tetrahydrate, 10 g / L glucose.

[0137] In order to explore the effect of different culture medium components on the yield of deoxypurpurogenin, strain B3EC was fermented in four culture media respectively, and the culture conditions were the same as those in the culture medium of "I. Production of deoxypurpurogenin by shake flask fermentation" in this example. The bar graph of the deoxypurpurogenin yield of strain B3EC in four culture media is shown in Figure 2. Figure 4 shown.

[0138] 3. Optimization of tryptophan addition

[0139] The B3EC engineered strain constructed in Example 2 was inoculated into LB liquid medium, cultured overnight at 37°C, 210rpm for 12h to obtain seed solution, and 500μL of seed solution was inoculated into 25mL of M9-YE fermentation medium (containing 7mM, 14mM, 24mM, and 14mM was added during inoculation and 10mM was added again after 24 hours) to explore the effect of tryptophan addition method and concentration on the yield of deoxypurpurogenin, and other culture conditions remained unchanged. The bar graph of deoxypurpurogenin yield of strain B3EC in M9-YE medium with different concentrations of tryptophan added is shown in Figure 2. Figure 5 shown.

[0140] 4. Effect of increasing the expression of plasmid optimized enzyme on the yield of deoxypurpurogenin

[0141] The engineered strains B3EC-A, B3EC-B, B3EC-E, B3EC-C, B3EC-AB and B3EC-EC constructed in Example 2 were inoculated into LB liquid medium, cultured overnight at 37°C, 210rpm for 12h to obtain seed solution, and 500μL of seed solution was inoculated into 25mL of M9-YE fermentation medium (14mM tryptophan was added during inoculation and 10mM was added again after 24 hours) to explore the effect of strains after optimizing enzyme expression on the production of deoxypurpurogenous bacterium, and other culture conditions remained unchanged. The bar graph of deoxypurpurogenous bacterium production of different engineered strains in M9-YE medium is shown in Figure 6 shown.

[0142] The color comparison chart of the deoxypurpurogenin sample, the deoxypurpurogenin standard sample and the blank control extracted from the fermentation broth obtained after the strain B3EC-AB was fermented in M9-YE medium and diluted 150 times is shown in the figure. Figure 7 As shown, the blank control is DMSO solvent, and the concentration of the deoxypurpurogenin standard is 12.5 mg / L; the powder obtained after the centrifugation of the bacterial cell of the strain B3EC-AB fermentation broth is freeze-dried and ground is shown in the figure. Figure 8 shown.

[0143] Depend on Figures 3 to 8 It can be seen that after fermentation, strains BEC, B1EC, B2EC and B3EC, strain B3EC with three gene knockouts has the highest yield; compared with strain BEC, the yield of deoxypurpurogenous bacteriocin in strain B3EC increased from 0.378g / L to 1.061g / L, an increase of 1.81 times. The results of medium optimization show that a higher yield of purpurogenous bacteriocin can be obtained using M9-YE medium. When 7mM tryptophan is added as a precursor, the maximum production of deoxypurpurogenous bacteriocin is 1.061g / L in a shake flask culture for 48h. The present invention then optimizes the addition method and amount of tryptophan. The addition of 14mM tryptophan during inoculation and then adding 10mM again after 24 hours of induction increases the yield of the B3EC strain to 2.401g / L. In order to further strengthen the expression of pathway enzymes related to the synthesis of deoxyviolacein, a second plasmid (i.e., plasmid pET-tac-vioA-vioB) was transferred into the B3EC strain. The resulting engineered strain B3EC-AB produced 3.280 g / L deoxyviolacein under the condition of adding 24 mM tryptophan in batches, with significant yield and cost advantages, providing a reference for the subsequent development of more advantageous engineering strains.

[0144] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A genetically engineered strain producing deoxypurpurogenin, characterized in that: The method uses Escherichia coli as a starting strain, knocks out at least one of the tnaA gene, trpR gene or pheA gene in the Escherichia coli, and heterologously expresses the vioA gene, vioB gene, vioC gene and vioE gene; Wherein, the vioA gene, vioB gene, vioC gene and vioE gene are derived from Chromobacterium violaceum and obtained by codon optimization; The nucleotide sequence of the vioA gene is shown in SEQ ID NO.1; The nucleotide sequence of the vioB gene is shown in SEQ ID NO.2; The nucleotide sequence of the vioC gene is shown in SEQ ID NO.3; The nucleotide sequence of the vioE gene is shown in SEQ ID NO.

4.

2. The genetically engineered strain producing deoxypurpurogenin according to claim 1, characterized in that: The Chromobacterium violaceum is Chromobacterium violaceum ATCC 12472; and / or The Escherichia coli is Escherichia coli BL21 (DE3).

3. The genetically engineered strain producing deoxypurpurogenin according to claim 1 or 2, characterized in that: The heterologous expression includes using a strong promoter to control the expression of the vioA gene, vioB gene, vioC gene and vioE gene.

4. The genetically engineered strain producing deoxypurpurogenin as claimed in claim 3, characterized in that: The strong promoter is P tac .

5. A method for constructing a genetically engineered strain producing deoxyviolacein according to any one of claims 1 to 4, characterized in that: The construction method includes the following steps: Step 1. Preparation of knockout E. coli strains Using CRISPR / Cpf1 gene editing technology, knocking out at least one of the tnaA gene, the trpR gene or the pheA gene in the Escherichia coli to obtain a knockout Escherichia coli strain; Step 2: Construction of recombinant expression vector Using the genome of Chromobacterium violaceum as a template, a plasmid containing vioA gene, vioB gene, vioC gene and vioE gene was constructed to obtain a recombinant expression vector; Step 3: Construction of a genetically engineered strain producing deoxypurpurogenin The recombinant expression vector is introduced into the knockout Escherichia coli strain to obtain the genetically engineered strain producing deoxypurpurogenin.

6. The method for constructing a genetically engineered strain producing deoxypurpurogenin according to claim 5, characterized in that: The step 1 specifically includes the following steps: S11. Using the E. coli BL21 genome as a template, connect the upstream and downstream fragments of the trpR gene to obtain donor DNA fragment 1; S12. The N23 sequence on the plasmid pcrEG was replaced with the N23' sequence complementary to the specific 23 bp sequence on trpR, and trpR-N23-F / R was used as primers to obtain the plasmid pcrEG-TrpR with targeting trpR; S13. The pEcCpf1 plasmid was transformed into competent E. coli cells to obtain BL21-pEcCpf1 strain; S14. Introduce the pcrEG-TrpR plasmid and donor DNA fragment 1 into competent cells of the BL21-pEcCpf1 strain, culture, remove the pcrEG-TrpR plasmid and the pEcCpf1 plasmid, and obtain Escherichia coli with knockout of the trpR gene, namely the B1 strain.

7. The method for constructing a genetically engineered strain producing deoxypurpurogenin according to claim 6, characterized in that: The step 1 further comprises taking the B1 strain as the starting strain, knocking out at least one of the pheA gene or the tnaA gene, and constructing a knockout Escherichia coli strain; and / or The step 2 comprises using the genome of Chromobacterium violaceum as a template, synthesizing the genes vioA, vioB, vioE and vioC by codon optimization, and constructing the plasmid pCO-tac-vioA-vioB-tac-vioE-vioC; and / or Using pETDuet-1 plasmid as a vector, at least one of the plasmids pET-tac-vioA, pET-tac-vioB, pET-tac-vioE, pET-tac-vioC, pET-tac-vioA-vioB or pET-tac-vioE-vioC was obtained by assembling two fragments.

8. The method for constructing a genetically engineered strain producing deoxypurpurogenin according to claim 7, characterized in that: The step three includes introducing the plasmid pCO-tac-vioA-vioB-tac-vioE-vioC and at least one of pET-tac-vioA, pET-tac-vioB, pET-tac-vioE, pET-tac-vioC, pET-tac-vioA-vioB or pET-tac-vioE-vioC into the knockout Escherichia coli strain.

9. Use of the deoxyviolacetin-producing genetically engineered strain obtained by the construction method of the deoxyviolacetin-producing genetically engineered strain according to any one of claims 1 to 4 or the deoxyviolacetin-producing genetically engineered strain according to any one of claims 5 to 8 in the synthesis of deoxyviolacetin.

10. The use according to claim 9, characterized in that: The genetic engineering strain producing deoxyviolacein is fermented and cultured in a fermentation medium containing tryptophan to produce deoxyviolacein.

Citation Information

Cited By

  • Recombinant escherichia coli for producing deoxyviolacein and application thereof

    CN118979051A

  • A genetically engineered strain with high deoxyactinomycin production and application thereof

    CN122706579A